Trade Ideas September 18, 2026 12:59 PM

Planet Labs: Oversold Now, Reaccelerating Revenue Later - A Mid-Stage Long Trade

Q2/Q3 execution and a $900M backlog make today’s pullback an actionable opportunity — trade plan below.

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
PL

Planet Labs (PL) has been punished since its May peak, but recent results show record revenue, beat-and-raise execution and a growing government backlog. Technicals are oversold and short interest remains elevated, creating a tactical asymmetric long setup. This trade targets a mean-reversion + multiple expansion move over the next 45 trading days with a backup plan for a longer hold.

Planet Labs: Oversold Now, Reaccelerating Revenue Later - A Mid-Stage Long Trade
PL
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Record quarterly revenue $116.05M and 58% YoY growth - execution continues.
  • Backlog near $900M provides revenue visibility and supports future quarters.
  • Technicals oversold (RSI 28.4) and elevated short interest create asymmetric upside.
  • Trade plan: Long entry $16.20, target $28.00, stop $13.00, mid term (45 trading days).

Hook / Thesis

Planet Labs (PL) has been dragged down from its $51.76 peak to the current price area near $16.21. The sell-off looks driven more by rotation, dilution headlines and profit-taking than by any deterioration in the company's underlying growth. On the fundamentals side, Planet reported record quarterly revenue of $116.05 million and a reported beat on EPS ($0.02 vs consensus -$0.02). Backlog sits near $900 million, and year-over-year revenue growth remains strong - the business is growing, improving margins and winning higher-value government contracts.

Technicals and market structure now favor a tactical long: the stock is trading below its 10/20/50-day moving averages, the 14-day RSI is 28.4 (clearly oversold), and short interest remains significant. That combination creates scope for an outsized bounce if the company continues to execute and the market digests dilution concerns. The trade below treats the current pullback as an entry into a stronger business that simply needed a reset.

What Planet Labs Does - and why it matters

Planet provides daily earth-observation data from a large small-satellite constellation and a web-geo platform that turns imagery into operational insights. Customers include commercial firms and governments that use frequent imagery for mapping, agriculture, environmental monitoring and defense intelligence. The product sells on two axes: higher-frequency tasking/subscriptions and upgraded analytics/analytics-as-a-service. That combination translates into recurring revenue with potential for high lifetime value when customers integrate Planet’s feeds into operational workflows.

Why the market should care now

  • Growing revenue base - Planet delivered $116.05 million in the most recent quarter and reported 58% year-over-year revenue growth, evidence the business is scaling.
  • Large backlog - The company is operating off a roughly $900 million backlog, which gives visibility to future revenue and increases investor confidence that growth is sustainable.
  • Government & enterprise traction - Recent wins, including a German government contract and stronger government mix, indicate higher-value, sticky revenue that can lift average contract sizes and margins over time.
  • Market dislocation - The stock has pulled back from $51.76 to ~ $16.21 while the business grew revenue and beat expectations, creating a tactical entry opportunity for a risk-aware long.

Hard numbers

  • Latest reported quarter: revenue $116.05 million; EPS $0.02 (beat consensus).
  • Year-over-year revenue growth: ~58% in the most recently reported quarter.
  • Backlog: ~ $900 million (company commentary and reporting highlights).
  • Market cap: approximately $5.9 billion.
  • Shares outstanding: ~363.8 million.
  • Free cash flow (trailing): $22.3 million.
  • Balance sheet ratios: current ratio ~2.84 and debt-to-equity ~0.79, suggesting manageable leverage.
  • Valuation ratios: price-to-sales ~16.34 and price-to-book ~10.95 - the market is still assigning premium multiples despite the recent share price decline.
  • Technical data: 14-day RSI 28.44 (oversold); 10-day SMA $16.77; 50-day SMA $21.18; 52-week range $10.22 - $51.76.
  • Short interest: recent settlement shows ~29.2 million shares short with days-to-cover around 5.9 days, creating potential squeeze dynamics on positive news.

Valuation framing

At a market cap near $5.9 billion and recent revenue run-rate north of $400 million annualized pace implied by quarterly results, the market is pricing considerable growth and execution. Price-to-sales of ~16.3 and price-to-book near 11 reflect expectations for both strong growth and differentiated moat. That said, the multiple has come down with the share price slump from mid-year highs. The important point: the business is still unprofitable on GAAP, but the cadence of quarter-over-quarter revenue improvements and a growing government backlog give a path to improved margins and positive operating leverage. For a mid-term trading thesis, you don't need an immediate re-rating back to peak multiples; you only need a partial reversion to fairer multiples and better sentiment as execution continues.

Catalysts (what can move the stock higher)

  • Continued top-line beats and margin progression across the next one-to-two quarters, driven by backlog conversion and higher government contract mix.
  • Clarity on equity dilution plans - any reduction in planned issuance size or favorable pricing dynamics would remove a near-term overhang.
  • New high-value government awards and visible expansion in Europe (recent German contract cited) that increase sticky revenue.
  • Technical squeeze: elevated short interest + oversold technicals can produce swift mean reversion on positive headlines.
  • Improvement in free cash flow from operating leverage as recurring, subscription-like revenues scale.

Trade plan (actionable)

I propose a tactical long with the following parameters. This is a mid-term, swing trade designed to capture mean reversion and sentiment improvement over the next 45 trading days, with room to extend to a longer hold if execution continues.

Entry Target Stop Horizon Risk level
$16.20 $28.00 $13.00 Mid term (45 trading days) Medium

Rationale for levels:

  • Entry $16.20 sits inside today's intraday range and close to the 10-day SMA and current price; it offers a logical, liquid entry in oversold territory.
  • Target $28.00 represents a reclaim toward the 50-day area and partial recovery of multiple expansion as the market reassesses the growth and backlog conversion. It is still well below the 52-week high and assumes a modest re-rating, not a full return to peak multiples.
  • Stop $13.00 protects capital should revenue/macro execution falter or dilution fears intensify. It is below recent swing lows and limits downside to a controlled level.
  • Horizon mid term (45 trading days) aims to capture a sentiment re-rate after one or two subsequent positive data points (quarterly updates, government contract wins, or clarity on capital raises). If the company materially improves metrics, extend to long term (180 trading days) and tighten stops.

Risks and counterarguments

  • Dilution risk: Management has discussed equity issuance plans (a previously planned $1.5 billion offering was part of recent headlines). Any large-scale share issuance could pressure the stock and offset fundamental progress.
  • Profitability path: The company is still unprofitable on GAAP (EPS -$0.99 on trailing metrics) and free cash flow is modest ($22.3 million). If revenue growth slows or margins deteriorate, the multiple compresses quickly.
  • Government concentration: Increased government revenue is good for backlog but can concentrate counterparty risk and extend sales cycles; if government spending shifts, revenues could be volatile.
  • Macro/valuation compression: Markets can punish high-multiple growth names during risk-off stretches. With price-to-sales near 16x, PL carries re-rating risk if risk appetite falls.
  • Insider selling headlines: Recent director/CFO/CEO stock sales (via Rule 10b5-1 or sell-to-cover mechanics) have been flagged by the market and can be misread as lack of conviction despite being largely procedural or tax-driven.

Counterargument - Someone could reasonably argue that the remaining valuation premium already prices in the best-case execution and the recent bounce in Q2/Q3 results won't be enough to justify the multiples unless Planet proves durable, margin-accretive growth. If the company issues equity at materially dilutive prices or misses future quarters, the stock could revisit single digits. That is a credible outcome and the primary reason for a defined stop at $13.00.

What would change my mind

  • I would abandon the bullish stance if revenue growth decelerates meaningfully below guidance or backlog conversion stalls for multiple quarters.
  • Materially dilutive equity issuance priced well below current market levels would also change my view by resetting expectations on ownership and intrinsic value.
  • Conversely, sustained sequential margin improvement, consistent free cash flow growth and visible multi-quarter government contract wins would push me to increase position size and move the target higher.

Conclusion

Planet Labs is a high-growth, capital-intensive technology services business that has delivered record revenue and is converting a substantial backlog into near-term visibility. The market has overreacted to dilution headlines and profit-taking, creating an asymmetric trade setup. The proposed mid-term long stakes a position with a clear stop at $13.00 and a realistic target at $28.00 tied to partial multiple recovery and improved sentiment. Keep position sizing conservative and monitor upcoming corporate flows and any new equity plans closely - those will be the primary near-term price drivers that can either validate or invalidate this trade.

Risks

  • Planned or executed equity issuance could materially dilute existing shareholders and pressure the share price.
  • Company remains unprofitable on GAAP (trailing EPS weakness) and modest free cash flow; slower-than-expected margin improvement would compress multiples.
  • High government revenue concentration can introduce contract timing risk and longer sales cycles.
  • Market-wide risk-off periods can sharply re-rate high-valuation growth names despite company-level execution.

More from Trade Ideas

Enova Is Oversold After a Regulatory Setback - Upgrade to Buy for a Tactical Swing Sep 18, 2026 Buy Now Before The AI-Cloud Repricing: A Practical Nvidia Trade Plan Sep 18, 2026 Buy PAA for Yield and Restructuring Optionality: 7% Income, Cheap Cash Flow, Reasonable Balance Sheet Sep 18, 2026 Infosys: Oversold on Charts, But Fundamentals Don’t Back a Durable Bounce Sep 18, 2026 Applied Optoelectronics: Positioning for a Revenue Inflection as Capacity Ramps Sep 18, 2026